Skip to content

Clinical and laboratory characteristics of Remission and non-remission in Graves ophthalmopathy after immunosuppressive therapy

Clinical and laboratory characteristics of Remission and non-remission in Graves ophthalmopathy after immunosuppressive therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075496
Enrollment
Unknown
Registered
2023-09-06
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid related diseases (Graves ophthalmopathy)

Interventions

Inactive GO group:None
Active GO group:None
Control group undergoing surgery:None
GO group undergoing surgery:None

Sponsors

First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients who meet the diagnostic criteria for Graves' disease or Graves' ophthalmopathy and have not received immunosuppressive therapy The lender; (2) = 18 years old, ?65 years old; (3) the applicant agrees and signs the informed consent form;

Exclusion criteria

Exclusion criteria: (1) Patients with previous immunosuppressive therapy or optic nerve injury;(For patients undergoing surgical treatment, the use of hormones and immunosuppressants within the last 3 months can be excluded) (2) have been treated with corticosteroids or other immunosuppressants for other reasons within the past 3 months, or have taken probiotics or antibiotics within the past 4 weeks. (3) Patients with acute or chronic viral hepatitis, moderate or severe damage of liver and kidney function, acute infection, severe osteoporosis, high blood pressure and blood glucose, who cannot be controlled; (4) History of chronic diarrhea or constipation, inflammatory bowel disease, malignancy, other autoimmune diseases, history of gastrointestinal surgery, vegetarians; (5) pregnant or breastfeeding; Suspected or real drug abusers, alcohol addicts; (6) has a history of mental illness, or is judged by the investigator to be unfit to participate in the clinical study or unable to cooperate with the completion of the study.

Design outcomes

Primary

MeasureTime frame
Lipid metabolomics, intestinal flora, magnetic resonance imaging, and fibrocyte autophagy levels between groups;

Secondary

MeasureTime frame
Total cholesterol, triglycerides, low density lipoprotein, high density lipoprotein, cysteine-rich protein 61 among the groups (CYR61), cytokines (IL-6, IL-17, IL-10), IgG, IgG4, FT3, FT4, TSH, TPOAb, TgAb, TRAb, IOP, fundus photography, CAS score, GO-QOL score, perceived stress score, anxiety and depression score;

Countries

China

Contacts

Public ContactXu Jixiong

First Affiliated Hospital of Nanchang University

jixiong.xu@ncu.edu.cn+86 133 0708 6069

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026